As a tumor suppressor, miR-34a also participates in the therapy resistance of progressive NB since it targets crucial players of therapy resistance including N-MYC, E2F3, BCl2, CCND1, and CDK6 (Sun et al., 2008; Wei et al., 2008). Here, MYCN is linked to neoplasm.